The history of the field of biological psychiatry can be cynically encapsulated by
the quest to reverse engineer serendipitous clinical findings. The role of monoamines
in depression, dopamine in schizophrenia, and second messengers in bipolar disorder
have all been reversed engineered from understanding the effects of tricyclics, antipsychotics,
and lithium, respectively. In this context, the emergence of N-acetylcysteine (NAC) as a potential therapeutic modality provides a dual opportunity:
a novel therapy and a key to unlocking the pathophysiology of the targeted disorders.
One of the perplexing and curious things about NAC is that it appears to be of potential
value for a multitude of phenomena in a diversity of seemingly disparate disorders.
Mirroring what we have seen with atypical antipsychotics and even antidepressants,
efficacy patterns of NAC show little respect for the chapter structure of the DSM-IV
system. Positive trials are reported for negative and extrapyramidal symptoms in schizophrenia,
depression in bipolar disorder, cocaine craving, smoking cessation, trichotillomania,
and gambling (
1
). Given the frequency of negative studies for established agents, the paucity of
negative published studies is noteworthy.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Biological PsychiatryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action.J Psychiatry Neurosci. 2011; 36: 78-86
- A randomized controlled pilot trial of oral N-acetylcysteine in children with autism.Biol Psychiatry. 2012; 71: 956-961
- A systematic review of medical treatments for children with autism spectrum disorders.Pediatrics. 2012; 127: e1312-e1321
- Glutamatergic modulation of auditory information processing in the human brain.Biol Psychiatry. 2012; 71: 969-977
- Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients.Neuropsychopharmacology. 2008; 33: 2187-2199
- Oxidative pathways as a drug target for the treatment of autism.Expert Opin Ther Targets. 2010; 14: 1301-1310
- Glutathione: a novel treatment target in psychiatry.Trends Pharmacol Sci. 2008; 29: 346-351
- Repeated N-acetylcysteine administration alters plasticity-dependent effects of cocaine.J Neurosci. 2007; 27: 13968-13976
- Mitochondrial dysfunction in autism.JAMA. 2010; 304: 2389-2396
- Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors.Neurosci Biobehav Rev. 2011; 35: 804-817
Article info
Publication history
Accepted:
April 1,
2012
Received:
March 22,
2012
Identification
Copyright
© 2012 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Glutamatergic Modulation of Auditory Information Processing in the Human BrainBiological PsychiatryVol. 71Issue 11
- PreviewAuditory mismatch negativity (MMN) and P300 event-related potentials (ERPs) are reduced in schizophrenia patients and healthy volunteers administered the N-methyl-D-aspartate glutamate receptor antagonist, ketamine. In rodents, N-acetylcysteine (NAC), a stimulator of the cystine-glutamate exchanger, attenuates the cognitive and behavioral effects of N-methyl-D-aspartate receptor antagonists. On the basis of these findings, we tested whether NAC would reduce ketamine effects on behavior, MMN, and P300 in healthy humans.
- Full-Text
- Preview
- A Randomized Controlled Pilot Trial of Oral N-Acetylcysteine in Children with AutismBiological PsychiatryVol. 71Issue 11
- PreviewAn imbalance in the excitatory/inhibitory systems with abnormalities in the glutamatergic pathways has been implicated in the pathophysiology of autism. Furthermore, chronic redox imbalance was also recently linked to this disorder. The goal of this pilot study was to assess the feasibility of using oral N-acetylcysteine (NAC), a glutamatergic modulator and an antioxidant, in the treatment of behavioral disturbance in children with autism.
- Full-Text
- Preview
